X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs ALKEM LABORATORIES - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA ALKEM LABORATORIES TORRENT PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 27.8 - - View Chart
P/BV x 5.3 7.3 72.2% View Chart
Dividend Yield % 1.0 0.6 174.0%  

Financials

 TORRENT PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
ALKEM LABORATORIES
Mar-16
TORRENT PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,7681,589 111.3%   
Low Rs1,1861,232 96.2%   
Sales per share (Unadj.) Rs346.1417.5 82.9%  
Earnings per share (Unadj.) Rs55.256.3 98.0%  
Cash flow per share (Unadj.) Rs73.364.7 113.3%  
Dividends per share (Unadj.) Rs14.0012.70 110.2%  
Dividend yield (eoy) %0.90.9 105.3%  
Book value per share (Unadj.) Rs257.1292.9 87.8%  
Shares outstanding (eoy) m169.22119.57 141.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.33.4 126.3%   
Avg P/E ratio x26.825.1 106.8%  
P/CF ratio (eoy) x20.121.8 92.4%  
Price / Book Value ratio x5.74.8 119.3%  
Dividend payout %25.422.6 112.5%   
Avg Mkt Cap Rs m249,887168,653 148.2%   
No. of employees `00011.8NA-   
Total wages/salary Rs m9,9349,171 108.3%   
Avg. sales/employee Rs Th4,971.5NM-  
Avg. wages/employee Rs Th843.2NM-  
Avg. net profit/employee Rs Th792.4NM-  
INCOME DATA
Net Sales Rs m58,56949,915 117.3%  
Other income Rs m2,2331,645 135.7%   
Total revenues Rs m60,80251,561 117.9%   
Gross profit Rs m13,7738,482 162.4%  
Depreciation Rs m3,0691,006 305.2%   
Interest Rs m2,056671 306.5%   
Profit before tax Rs m10,8818,451 128.8%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5451,606 96.2%   
Profit after tax Rs m9,3366,731 138.7%  
Gross profit margin %23.517.0 138.4%  
Effective tax rate %14.219.0 74.7%   
Net profit margin %15.913.5 118.2%  
BALANCE SHEET DATA
Current assets Rs m53,84127,062 199.0%   
Current liabilities Rs m31,61215,324 206.3%   
Net working cap to sales %38.023.5 161.4%  
Current ratio x1.71.8 96.4%  
Inventory Days Days9767 146.1%  
Debtors Days Days8441 202.9%  
Net fixed assets Rs m42,07912,610 333.7%   
Share capital Rs m846239 353.9%   
"Free" reserves Rs m42,65534,490 123.7%   
Net worth Rs m43,50135,027 124.2%   
Long term debt Rs m22,4081,212 1,849.5%   
Total assets Rs m101,25054,387 186.2%  
Interest coverage x6.313.6 46.3%   
Debt to equity ratio x0.50 1,489.2%  
Sales to assets ratio x0.60.9 63.0%   
Return on assets %11.313.6 82.7%  
Return on equity %21.519.2 111.7%  
Return on capital %19.624.9 79.0%  
Exports to sales %012.9 0.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m20,0666,563 305.7%   
Fx outflow Rs m5,3043,012 176.1%   
Net fx Rs m14,7623,552 415.7%   
CASH FLOW
From Operations Rs m10,1277,259 139.5%  
From Investments Rs m-7,8691,864 -422.1%  
From Financial Activity Rs m-1,918-9,273 20.7%  
Net Cashflow Rs m212-150 -141.0%  

Share Holding

Indian Promoters % 71.5 66.9 106.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 33.1 21.2%  
FIIs % 12.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 0.0 -  
Shareholders   26,511 68,381 38.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   CIPLA  PIRAMAL ENTERPRISES  ALEMBIC PHARMA  SHASUN PHARMA  PFIZER  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Feb 21, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - VENUS REMEDIES COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS